Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
SP
-
São Paulo, SP, Brazil
- Systemic Sclerosis Outpatient Clinic, Hospital São Paulo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fulfill Systemic sclerosis EULAR/American College of Rheumatology 2013 classification criteria;
- Pharmacological treatment with stable dosages for the last three months.
Exclusion Criteria:
- Pregnancy;
- Use of anticoagulants, NSAIDs or antiplatelets drugs;
- Diagnose of other autoimmune rheumatic diseases, coronary diseases, cerebrovascular diseases and severe peripheral artery diseases;
- Active infection;
- Contraindication to acetylsalicylic acid use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: ASA group
Pill containing 100 mg of acetylsalicylic acid, taken once daily for 04 weeks
|
Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
|
|
PLACEBO_COMPARATOR: Placebo oral capsule group
Identical pill containing placebo, taken once daily for 04 weeks
|
Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum level of thromboxane B2
Time Frame: Baseline and 4 weeks
|
Measured by ELISA
|
Baseline and 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum level of platelet-derived, endothelial-derived and monocyte-derived microparticles
Time Frame: Baseline and 4 weeks
|
Measured by flow cytometry
|
Baseline and 4 weeks
|
|
Serum level of von Willebrand factor
Time Frame: Baseline and 4 weeks
|
Measured by ELISA
|
Baseline and 4 weeks
|
|
Serum level of endothelin-1
Time Frame: Baseline and 4 weeks
|
Measured by ELISA
|
Baseline and 4 weeks
|
|
Digital blood flow
Time Frame: Baseline and 4 weeks
|
Measured by laser Doppler imaging
|
Baseline and 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Cristiane Kayser, PhD, Federal University of São Paulo
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Connective Tissue Diseases
- Sclerosis
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
Other Study ID Numbers
- 0246/2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.